source
- Experts debate extra regulation for low-risk digital wellness devicesTwo recent papers published in JAMA have highlighted concerns about low-risk digital health technologies that consumers use. Experts say that even though these tools are considered low-risk, they…
- Supernus and Indivior merge to form CNS-focused company with 11 marketed drugs and $2.2B revenue targetSupernus Pharmaceuticals and Indivior Pharmaceuticals announced an all‑stock merger of equals, creating a central nervous system‑focused company that will combine their product lines and operations…